<DOC>
	<DOCNO>NCT01464697</DOCNO>
	<brief_summary>The purpose study test whether oral micronized progesterone reduces Vasomotor Symptom Score comprise number severity hot flush night sweat perimenopausal woman . Oral micronized progesterone molecularly identical human progesterone , steroid hormone . It sell prescription use prevent endometrial cancer woman take estrogen menopause . This research study test whether progesterone reduces perimenopausal hot flush night sweat . It also test whether progesterone improve sleep disturbance anxiety .</brief_summary>
	<brief_title>Oral Micronized Progesterone Perimenopausal Vasomotor Symptoms</brief_title>
	<detailed_description>This randomize , double-blind placebo-controlled trial oral micronized progesterone ( 300 mg daily bedtime ) perimenopausal woman live anywhere Canada . Using self-reported maximum menstrual cycle length previous year , woman stratify Early Perimenopause ( &lt; 60 day ) Late Perimenopause ( &gt; =60 day ) . The design include 28-day baseline run-in follow 12 week randomize therapy .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . Between 3558 year age 2 . At least 4 vasomotor symptom ( VMS ) per day , average , least 2/4 week least 56 fourweek period . In addition , woman report VMS moderate severe rather mild intensity . Women report few VMS , report night sweat awaken sleep two night per week also include . 3 . Perimenopausal status either base irregularity menstrual period , onset new perimenopausal symptom woman regular period . 4 . At least one menstrual period within 12 month study enrollment 5 . Ability willingness complete Daily Perimenopause Hot Flush Calendar record instrument . 6 . Ability understand , speak , read write English . 7 . Women high risk breast cancer ( ie first degree relative breast cancer , known/suspected history breast cancer ) require normal mammogram clinical breast examination within 12 month study enrollment . 1 . VMS without perimenopausal etiology . 2 . Women hysterectomy and/or ovariectomy . 3 . Peanut allergy ( peanut oil use progesterone formulation . ) 4 . Current recent ( within last 6mos . ) use hormonal therapy ( estrogen , progesterone , hormonal contraceptive , hormonal fertility treatment ) , plan initiate use study period . Two exception : woman use progestinreleasing intrauterine device ( IUD ) exclude felt level hormone release effect VMS woman take lowdose transdermal progesterone therapy VMS meet inclusion criterion consider casebycase basis . If enrol , require continue document use lowdose hormone therapy throughout entire trial . 5 . Planned pregnancy fertility treatment study period . 6 . Women breastfeed . 7 . Participants score great equal 15 Personal Health Questionnaire ( PHQ9 ) assess casebycase basis . Women assess need investigation and/or treatment depression exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hot flushes/hot flash</keyword>
	<keyword>night sweat</keyword>
	<keyword>sleep problem</keyword>
	<keyword>negative mood</keyword>
	<keyword>anxiety</keyword>
	<keyword>perimenopause</keyword>
	<keyword>progesterone</keyword>
	<keyword>vasomotor symptom</keyword>
	<keyword>premenopause</keyword>
</DOC>